Welcome to our dedicated page for Greenland Mines SEC filings (Ticker: GRML), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Greenland Mines Ltd. filings document the company's public-company status, Nasdaq-listed common stock and warrants, governance changes, reporting obligations, and corporate identity after its former name, Klotho Neurosciences, Inc.. Recent Form 8-K records include board composition matters and Nasdaq compliance disclosures, while Form 12b-25 records address timing for an annual report filing.
The filing record identifies Greenland Mines as a Delaware corporation and an emerging growth company. Its disclosures also provide formal context for the company's registered securities, corporate governance, reporting status, and material-event reporting as it operates across natural resources and cell and gene therapy activities.
Greenland Mines Ltd submitted a Form 12b-25 notifying the SEC that it cannot timely file its Annual Report on Form 10-K for the period ended December 31, 2025. The company states the delay is due to time required for final revisions and coordination of exhibits. The filing was signed by CEO Joseph A. Sinkule on April 1, 2026.
Greenland Mines Ltd has received an additional 180-day period, through September 14, 2026, to regain compliance with Nasdaq’s minimum $1.00 per share bid price requirement. The company must achieve a closing bid of at least $1.00 for 10 consecutive business days within this window or its common stock will be subject to delisting from Nasdaq.
The extension reflects that Greenland Mines currently meets all other Nasdaq listing standards, including market value of publicly held shares. The company highlights two divisions: Natural Resources, anchored by the Skaergaard Project in Southeast Greenland with a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq, and Cell and Gene Therapy, including the KLTO-202 program for ALS.